Venus Remedies

Venus Remedies FCF Margin

The Free Cash Flow Margin of Venus Remedies (VENUSREM.NS) as of Nov 10, 2026 is 15.54 %. In the previous year, Free Cash Flow Margin was 12.55 % — a change of 23.88% (higher).

FCF Margin

15.54 %

YoY

23.88%

Last updated:

Free Cash Flow Margin of Venus Remedies is 2026 15.54 % . Free Cash Flow Margin of Venus Remedies was 2025 12.55 % . It decreases by 23.88% higher compared to the previous year.

The Venus Remedies FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2019
11.15 INR
Jan 1, 2020
20.57 INR
Jan 1, 2021
22.78 INR
Jan 1, 2022
4.56 INR
Jan 1, 2023
5.18 INR
Jan 1, 2024
4.73 INR
Jan 1, 2025
12.55 INR
Jan 1, 2026
15.54 INR
The Venus Remedies FCF Margin history
YEARFCF MarginYoY
15.54 %+23.88%
12.55 %+165.34%
4.73 %-8.80%
5.18 %+13.72%
4.56 %-79.99%
22.78 %+10.79%
20.57 %+84.38%
11.15 %+10.36%
10.11 %-18.89%
12.46 %-1,542.93%
-0.86 %-1,148.49%
0.08 %-101.05%
-7.84 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Venus Remedies Stock analysis

What does Venus Remedies do? Venus Remedies Ltd. manufactures and trades pharmaceutical products, focusing on injectables, tablets, and topical preparations for therapeutic segments including anti-infective, oncology, skin and wound care, and pain management. The company's brands such as Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, Ventaful, and Nervolize cater to critical care and super specialty markets. Its product portfolio addresses antimicrobial resistance (AMR), oncology, neurology, anticoagulants, and herbal solutions, serving medicine, surgery, neuro, and orthopedics. The firm operates in the Pharmaceutical Formulation segment with three manufacturing facilities. The company sells its pharmaceutical products to healthcare providers and institutions globally, targeting critical care and super specialty segments. Brands like Potentox and Vancoplus Combi are positioned for antimicrobial resistance (AMR) solutions, while Neurotol and Trois serve neurology and orthopedics. Supime and Zydotum focus on pain management and skin care, and Septiloc and Mucomelt address anticoagulants and wound care. Venus Remedies' formulations include injectables, tablets, and topical preparations for diverse therapeutic needs. Venus Remedies Ltd. generates revenue through the sale of its branded pharmaceutical products, including injectables, tablets, and topical preparations. The company's product lines target specific therapy areas such as AMR, oncology, skin and wound care, and pain management, with brands like Ventaful and Nervolize supporting neurology and anticoagulant markets. The firm's global reach in injectable manufacturing and focus on super specialty segments drive its market positioning within the Pharmaceutical Formulation segment. Venus Remedies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Venus Remedies stock

Free Cash Flow Margin of Venus Remedies is 15.54 % in 2026.

Free Cash Flow Margin of Venus Remedies changed from 12.55 % to 15.54 %, representing a 23.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Venus Remedies since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Venus Remedies with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Venus Remedies

All Key Metrics — Venus Remedies